Dianthus Therapeutics (DNTH)
Develops self-injected complement and dual-pathway therapies for severe autoimmune diseases.
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,584 shares of the company's stock after buying an additional
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H'28 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE'26 Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December '26 Building a rheumatology franchise with DNTH212 across our first three prioritized indications of Sjögren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM); Phase 1 healthy volunteer data anticipated by YE'26 Advancing DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases; DNTH312 aims to be Phase 1 ready by YE'27 Approximately $1.2 billion of cash as of June 30, 2026 provides expected runway into 2030 NEW YORK and WALTHAM, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2026, and provided an update on other recent business achievements.
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs By building on claseprubart's best-in-class profile, DNTH312 strengthens Dianthus' leadership in neuromuscular disease, while expanding into additional autoimmune diseases where both B cell modulation and Classical Pathway inhibition could provide additional benefits to more patients DNTH312 aims to be Phase 1 ready by YE'27 NEW YORK and WALTHAM, Mass.
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics to Participate in Two Investor Conferences
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026.
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China).
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.82 per share a year ago.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr.
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero.
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
JPMorgan Chase and Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 626.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,124 shares of the company's stock after purchasing an additional 58,746 shares during
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.